RBC Capital downgraded Fisher & Paykel Healthcare to Underperform from Sector Perform with a price target of NZ$29, down from NZ$30. The downgrade follows the company’s FY25 results, which exceeded both RBC and consensus expectations, but showed a “significant slowdown” in revenue growth of hospital new application consumables and homecare consumables. The firm cited the stock’s “expensive valuation relative to its earnings outlook” for the downgrade.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FSPKF:
- Fisher & Paykel Healthcare Surpasses $2 Billion Revenue Milestone
- Fisher & Paykel Healthcare Announces Dividend Distribution
- Fisher & Paykel Healthcare Achieves Record Revenue in 2025
- Fisher & Paykel Healthcare Announces Investor Event in Melbourne
- Pinnacle Investment Reduces Stake in Fisher & Paykel Healthcare